Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 101

Sort by

Sort Order Select

Journal Articles

Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refractory (R/R) Epstein-Barr Virus (EBV)-Positive B-Cell, T-Cell, and Hodgkin Lymphoma: Interim Safety and Efficacy Results from a Phase 1b/2a Study

Blood (2019) 134 (Supplement_1): 465.

https://doi.org/10.1182/blood-2019-132004

Published: 2019

Journal Articles

Bone Marrow Ribonucleotide Reductase mRNA Levels and Methylation Status As a Prognostic Factor in Patients with Myelodysplastic Syndrome Treated with 5-Azacytidine

Christina-Nefeli Kontandreopoulou, BSc, Panagiotis T Diamantopoulos, MD PhD, Argiris Symeonidis, MD PhD, Ioannis Kotsianidis, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Andreas Giannopoulos, BSc, MSc, Katerina Zoi, PhD, Maria Dimou, MD PhD, Elena E. Solomou, MD, Panayiotis Panayiotidis, MD, Georgios Kyriakakis, Nefeli Giannakopoulou, Georgios Dryllis, Sevastianos Chatzidavid, Nora-Athina Viniou, MD PhD

Blood (2019) 134 (Supplement_1): 1721.

https://doi.org/10.1182/blood-2019-126426

Published: 2019

Journal Articles

An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS

Tapan M. Kadia, MD, Gautam M. Borthakur, MD, Elias Jabbour, MD, Marina Y Konopleva, MD PhD, Farhad Ravandi, MD, Courtney D. DiNardo, MDMSc, Daniella Zheleva, PhD, David Blake, PhD, Judy H Chiao, MD

Blood (2019) 134 (Supplement_1): 3926.

https://doi.org/10.1182/blood-2019-131930

Published: 2019

Journal Articles

Pralatrexate-Resistant Cell Lines Show Intact Internalization Via RFC1 but Collateral Sensitivity to Nucleoside Analogs

Kana Oiwa, MD, Naoko Hosono, MD, Rie Nishi, PhD, Takanori Ueda, MD PhD, Luigi Scott, PhD, Owen A. O'Connor, MD, PhD, Takahiro Yamauchi, MD PhD

Blood (2018) 132 (Supplement 1): 3961.

https://doi.org/10.1182/blood-2018-99-110147

Published: 2018

Journal Articles

5-Fluorotroxacitabine Displays Potent Anti-Leukemic Effects and Circumvents Resistance to Ara-C

Aniket Bankar, MBBS, MD DM, Thirushi Piyumika Siriwardena, Biljana Rizoska, PhD, Christina Rydergård, BSc, Helen Kylefjord, BSc, Vilma Rraklli, PhD, Anders Eneroth, PhD, Pedro Pinho, PhD, Stefan Norin, MD PhD, Johan Bylund, PhD, Sara Moses, PhD, Richard Bethell, PhD, Simon Kavanagh, MBBS(Hons), FRACP, FRCPA, Xiaoming Wang, Rose Hurren, BSc, Mark D. Minden, MD PhD, Paul Targett-Adams, PhD BSc, Aaron D Schimmer, MD PhD, Mark Albertella, PhD

Blood (2018) 132 (Supplement 1): 3939.

https://doi.org/10.1182/blood-2018-99-114345

Published: 2018

Journal Articles

Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 4039.

https://doi.org/10.1182/blood-2018-99-119271

Published: 2018

Journal Articles

Disulfiram May Contribute to Apoptosis of Myeloma Cells By Reactivating of Cell Cycle Regulating Gene CDKN2A

Denisa Hrckova Drozdkova, Jan Gursky, PhD, Petra Luzna, Sabina Sevcikova, PhD, Jiri Minarik, MD PhD, Katerina Smesny Trtkova, PhD

Blood (2018) 132 (Supplement 1): 5125.

https://doi.org/10.1182/blood-2018-99-114743

Published: 2018

Journal Articles

Prognosis interfered with by clonal interference

Gautam Borthakur

Blood (2018) 132 (2): 118–119.

https://doi.org/10.1182/blood-2018-05-848390

Published: 2018

Journal Articles

Gemcitabine/Clofarabine/Busulfan: A New Myeloablative Reduced-Toxicity Conditioning Regimen with High Activity for Allogeneic Stem-Cell Transplant (alloSCT) in Aggressive Lymphomas

Yago Nieto, MD PhD, Peter F Thall, Benigno C Valdez, PhD, Junsheng Ma, MS, Melissa Timmons, Michelle Trapp, Sairah Ahmed, MD, Elizabeth J Shpall, MD, Roy B Jones, MDPhD, Chitra Hosing, MD, Paolo Anderlini, Uday Popat, MD, Muzaffar H. Qazilbash, MD, Amin Alousi, MD, Alison M Gulbis, PharmD, Celina Ledesma, Richard E. Champlin, MD, Borje S Andersson, MDPhD

Blood (2017) 130 (Supplement 1): 1966.

https://doi.org/10.1182/blood.V130.Suppl_1.1966.1966

Published: 2017

Journal Articles

CG '806, a Novel Pan-FLT3/BTK Multi-Kinase Inhibitor, Induces Cell Cycle Arrest, Apoptosis or Autophagy in AML Cells Depending on FLT3 Mutation Status

Guopan Yu, MD, PhD, Weiguo Zhang, MD PhD, Charlie Ly, BS, Hongying Zhang, MD, William Rice, PhD, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 4629.

https://doi.org/10.1182/blood.V130.Suppl_1.4629.4629

Published: 2017

Journal Articles

Final Results of Phase 2, Open-Label Study of E7070, Idarubicin and Cytarabine in Patients (Pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Rita Assi, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Tapan Kadia, MD, Naveen Pemmaraju, MD, Elias J. Jabbour, MD, Nitin Jain, MD, Naval Daver, MD, Taisuke Uehara, Takashi Owa, PhD, Gautam Borthakur, MD

Blood (2017) 130 (Supplement 1): 1380.

https://doi.org/10.1182/blood.V130.Suppl_1.1380.1380

Published: 2017

Journal Articles

Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

Blood (2016) 128 (22): 1639.

https://doi.org/10.1182/blood.V128.22.1639.1639

Published: 2016

Journal Articles

Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia Relapsing after Allogeneic Stem Cell Transplantation

Jessica I Hoell, MD, Sebastian Ginzel, MSc, Cornelia Eckert, PhD, Michael Gombert, PhD, Ute Fischer, PhD, Martin Stanulla, MD, Martin Schrappe, MD PhD, Udo zur Stadt, PhD, Peter Bader, MD, Brigitte Strahm, MD, Julia Alten, Anja Moericke, MD, Gabriele Escherich, MD, Arend Stackelberg, MD, Christina Peters, MD, Arndt Borkhardt, MD, Roland Meisel, MD

Blood (2016) 128 (22): 601.

https://doi.org/10.1182/blood.V128.22.601.601

Published: 2016

Journal Articles

Busulfan (Bu) in Combination with Double Nucleoside Analogues Fludarabine (Flu) and Clofarabine (Clo) Plus Vorinostat As a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Leukemia

Blood (2016) 128 (22): 64.

https://doi.org/10.1182/blood.V128.22.64.64

Published: 2016

Journal Articles

Characteristics, Outcomes and Treatment of Patients with T-Cell Prolymphocytic Leukemia (T-PLL) - Single-Center Experience

Etsuko Aoki, MDPhD, Preetesh Jain, MBBS, MDDM, PhD, Alessandra Ferrajoli, MD, Zeev Estrov, MD, Michael Keating, MBBS, Susan M. O'Brien, MD, William G. Wierda, MD PhD, Nitin Jain, MD, Philip A Thompson, MBBS, Elias Jabbour, MD, Sherry Pierce, BSN, BA, Chitra Hosing, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Tapan M. Kadia, MD

Blood (2016) 128 (22): 2997.

https://doi.org/10.1182/blood.V128.22.2997.2997

Published: 2016

Journal Articles

Inhibition of ATR in Combination with Nucleoside Analogues Eradicates Acute Myeloid Leukaemia in an Orthotopic Murine Xenograft Model

Sarah E Fordham, PhD, Helen J Blair, PhD, Claire J Elstob, PhD, Deepali Pal, PhD, Nicola Curtin, PhD, Paul Milne, PhD, Matthew Collin, MD PhD, Graham H Jackson, MD MBBS, Helen J Marr, MD PhD, Olaf Heidenreich, PhD, Ruth Plummer, John Pollard, PhD, Tobias F. Menne, MD PhD FRCPath, Gail L Jones, MD BMBS, James M Allan, DPhil

Blood (2016) 128 (22): 4031.

https://doi.org/10.1182/blood.V128.22.4031.4031

Published: 2016

Journal Articles

8-Chloro-Adenosine Inhibits Molecular Poor-Risk Acute Myeloid Leukemia (AML) and Leukemic Stem Cells (LSC) Growth and Synergizes with the BCL-2 Inhibitor Venetoclax (ABT-199)

Ralf Buettner, PhD, Ching-Cheng Chen, PhD, Bijender Kumar, PhD, Corey Morales, BA, BS, Lisa S Chen, PhD, Krister Wennerberg, PhD, Ryan Thompson, MS, Tea Pemovska, MSc, Ling Li, PhD, Bin Zhang, PhD, Claudia Kowolik, PhD, Mika Kontro, MD, Calum Leitch, MD, David Horne, PhD, Joycelynne Palmer, PhD, Varsha Gandhi, PhD, Guido Marcucci, MD, Vinod Pullarkat, MD, Steven T. Rosen, MD

Blood (2016) 128 (22): 2758.

https://doi.org/10.1182/blood.V128.22.2758.2758

Published: 2016

Journal Articles

8-Chloro-Adenosine Inhibits Molecular Poor-Risk Acute Myeloid Leukemia (AML) and Leukemic Stem Cells (LSC) Growth Via Novel RNA- and ATP-Directed Mechanisms: A Novel Therapeutic Approach for AML

Ralf Buettner, PhD, Ching-Cheng Chen, PhD, Bijender Kumar, PhD, Lisa S Chen, PhD, Krister Wennerberg, PhD, Ryan Thompson, MS, Tea Pemovska, MSc, Ling Li, PhD, Varsha Gandhi, PhD, Guido Marcucci, MD, Vinod Pullarkat, MD, Steven T. Rosen, MD

Blood (2015) 126 (23): 792.

https://doi.org/10.1182/blood.V126.23.792.792

Published: 2015

Journal Articles

Exquisite Sensitivity of Plasma Cell Malignancies to a Novel Nucleoside Analog Is Mediated By Overexpressed Adenosine Kinase

Utthara Nayar, Jouliana Sadek, Jonathan B Reichel, David Bunn, Denise Hernandez-Hopkins, Peter Barelli, Michelle Sahai, Jennifer Totonchy, Sei Shizuko, Robert Shoemaker, David Warren, Olivier Elemento, Kenneth Kaye, Ethel Cesarman

Blood (2015) 126 (23): 1812.

https://doi.org/10.1182/blood.V126.23.1812.1812

Published: 2015

Journal Articles

Efficacy and Toxicity of Nucleoside Analogs in Patients with Hairy Cell Leukemia Treated Outside Clinical Trials

Maria Luisa Guerrera, MD, Marzia Varettoni, MD, Alessandra Tedeschi, MD, Anna Maria Frustaci, MD, Virginia Valeria Ferretti, PhD, Luca Arcaini, Prof, Paola Picardi, MD, Silvia Zibellini, Sara Rattotti, MD, Roberto Cairoli, MD, Mario Cazzola, MD

Blood (2015) 126 (23): 5084.

https://doi.org/10.1182/blood.V126.23.5084.5084

Published: 2015

NARROW

Bone Marrow Ribonucleotide Reductase mRNA Levels and Methylation Status As a Prognostic Factor in Patients with Myelodysplastic Syndrome Treated with 5-Azacytidine

An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS

Pralatrexate-Resistant Cell Lines Show Intact Internalization Via RFC1 but Collateral Sensitivity to Nucleoside Analogs

5-Fluorotroxacitabine Displays Potent Anti-Leukemic Effects and Circumvents Resistance to Ara-C

Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

Disulfiram May Contribute to Apoptosis of Myeloma Cells By Reactivating of Cell Cycle Regulating Gene CDKN2A

Prognosis interfered with by clonal interference

Gemcitabine/Clofarabine/Busulfan: A New Myeloablative Reduced-Toxicity Conditioning Regimen with High Activity for Allogeneic Stem-Cell Transplant (alloSCT) in Aggressive Lymphomas

CG '806, a Novel Pan-FLT3/BTK Multi-Kinase Inhibitor, Induces Cell Cycle Arrest, Apoptosis or Autophagy in AML Cells Depending on FLT3 Mutation Status

Final Results of Phase 2, Open-Label Study of E7070, Idarubicin and Cytarabine in Patients (Pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia Relapsing after Allogeneic Stem Cell Transplantation

Busulfan (Bu) in Combination with Double Nucleoside Analogues Fludarabine (Flu) and Clofarabine (Clo) Plus Vorinostat As a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Leukemia

Characteristics, Outcomes and Treatment of Patients with T-Cell Prolymphocytic Leukemia (T-PLL) - Single-Center Experience

Inhibition of ATR in Combination with Nucleoside Analogues Eradicates Acute Myeloid Leukaemia in an Orthotopic Murine Xenograft Model

8-Chloro-Adenosine Inhibits Molecular Poor-Risk Acute Myeloid Leukemia (AML) and Leukemic Stem Cells (LSC) Growth and Synergizes with the BCL-2 Inhibitor Venetoclax (ABT-199)

8-Chloro-Adenosine Inhibits Molecular Poor-Risk Acute Myeloid Leukemia (AML) and Leukemic Stem Cells (LSC) Growth Via Novel RNA- and ATP-Directed Mechanisms: A Novel Therapeutic Approach for AML

Exquisite Sensitivity of Plasma Cell Malignancies to a Novel Nucleoside Analog Is Mediated By Overexpressed Adenosine Kinase

Efficacy and Toxicity of Nucleoside Analogs in Patients with Hairy Cell Leukemia Treated Outside Clinical Trials

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only